Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Recurrence 1Meningeal Neoplasms 1Inhibition, Psychological 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 45Radiotherapy 17Magnetic Resonance Spectroscopy 17Specimen Handling 14Bevacizumab 12pembrolizumab 11Lomustine 9Radiation 8fludarabine 7Cyclophosphamide 7atezolizumab 4Biopsy 4olaparib 3Transurethral Resection of Bladder 3Surgical Procedures, Operative 3Nivolumab 3Leukapheresis 3D2C7-(scdsFv)-PE38KDEL 3Blood Specimen Collection 3Aminolevulinic Acid 3regorafenib 2fluciclovine F-18 2contrast agent BR1 2antisecretory factor 2abemaciclib 2Restraint, Physical 2Re-Irradiation 2Radiation Dose Hypofractionation 2Palliative Care 2Oncolytic Virotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Glioblastoma × AZD1390 × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡